Volume 7, Issue 2, Pages (August 2010)

Slides:



Advertisements
Similar presentations
Volume 15, Issue 1, Pages (July 2014)
Advertisements

Volume 17, Issue 1, Pages (July 2015)
Volume 19, Issue 3, Pages (September 2016)
Volume 14, Issue 1, Pages (January 2014)
Volume 11, Issue 3, Pages (September 2012)
Volume 12, Issue 1, Pages (January 2013)
Volume 5, Issue 2, Pages (August 2009)
Volume 9, Issue 3, Pages (September 2011)
Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation  Melanie Wurm, John Kowalski, Dirk Heckl, Xiao-Bing.
Myung Jin Son, Kevin Woolard, Do-Hyun Nam, Jeongwu Lee, Howard A. Fine 
Volume 22, Issue 6, Pages (February 2018)
Volume 8, Issue 5, Pages (May 2017)
Francesca Ficara, Mark J. Murphy, Min Lin, Michael L. Cleary 
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Volume 14, Issue 3, Pages (September 2008)
Volume 11, Issue 12, Pages (June 2015)
Volume 2, Issue 4, Pages (April 2008)
Cited2 Is an Essential Regulator of Adult Hematopoietic Stem Cells
Volume 14, Issue 12, Pages (March 2016)
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Volume 3, Issue 5, Pages (November 2014)
Volume 17, Issue 10, Pages (December 2016)
Volume 28, Issue 2, Pages (August 2015)
Volume 2, Issue 4, Pages (April 2008)
Volume 4, Issue 2, Pages (February 2003)
Volume 14, Issue 1, Pages (January 2014)
HOXB4-Induced Expansion of Adult Hematopoietic Stem Cells Ex Vivo
Wenqian Hu, Bingbing Yuan, Harvey F. Lodish  Developmental Cell 
Volume 10, Issue 2, Pages (February 2012)
Mark J. Kiel, Melih Acar, Glenn L. Radice, Sean J. Morrison 
Volume 21, Issue 6, Pages (June 2012)
Volume 10, Issue 5, Pages (November 2004)
Volume 2, Issue 4, Pages (April 2008)
Volume 21, Issue 2, Pages (February 2013)
Volume 11, Issue 5, Pages (November 2018)
Volume 13, Issue 6, Pages (December 2013)
Volume 17, Issue 5, Pages (November 2015)
Kenichi Miharada, Valgardur Sigurdsson, Stefan Karlsson  Cell Reports 
Integrin Alpha 6 Regulates Glioblastoma Stem Cells
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
Volume 3, Issue 4, Pages (October 2014)
Volume 9, Issue 1, Pages (July 2011)
Volume 10, Issue 2, Pages (February 2018)
Volume 25, Issue 5, Pages e5 (October 2018)
Volume 28, Issue 5, Pages (May 2008)
Volume 9, Issue 2, Pages (August 2011)
SIRT3 Reverses Aging-Associated Degeneration
Imaging Hematopoietic Precursor Division in Real Time
Masayuki Yamashita, Eriko Nitta, Toshio Suda  Cell Stem Cell 
Volume 5, Issue 5, Pages (November 2015)
Volume 21, Issue 2, Pages (February 2012)
Volume 4, Issue 2, Pages (February 2009)
Volume 3, Issue 2, Pages (August 2008)
Volume 5, Issue 1, Pages (July 2009)
Volume 5, Issue 5, Pages (November 2015)
Volume 16, Issue 1, Pages (January 2015)
Volume 2, Issue 1, Pages (January 2008)
Volume 9, Issue 4, Pages (October 2011)
Hematopoietic Dysfunction in a Mouse Model for Fanconi Anemia Group D1
Volume 8, Issue 1, Pages (January 2011)
Volume 8, Issue 4, Pages (April 2017)
Volume 7, Issue 2, Pages (August 2010)
Volume 1, Issue 2, Pages (August 2007)
Tobias Maetzig, Jens Ruschmann, Lea Sanchez Milde, Courteney K
Volume 17, Issue 4, Pages (October 2015)
SLAM Family Markers Resolve Functionally Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors  Hideyuki Oguro, Lei Ding, Sean J.
Volume 2, Issue 3, Pages (March 2008)
Attenuation of miR-126 Activity Expands HSC In Vivo without Exhaustion
Volume 7, Issue 1, Pages (July 2010)
Volume 14, Issue 3, Pages (September 2008)
Presentation transcript:

Volume 7, Issue 2, Pages 186-197 (August 2010) A Distinctive DNA Damage Response in Human Hematopoietic Stem Cells Reveals an Apoptosis-Independent Role for p53 in Self-Renewal  Michael Milyavsky, Olga I. Gan, Magan Trottier, Martin Komosa, Ofer Tabach, Faiyaz Notta, Eric Lechman, Karin G. Hermans, Kolja Eppert, Zhanna Konovalova, Olga Ornatsky, Eytan Domany, M. Stephen Meyn, John E. Dick  Cell Stem Cell  Volume 7, Issue 2, Pages 186-197 (August 2010) DOI: 10.1016/j.stem.2010.05.016 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 IR-Induced Cellular Response in Hematopoietic Fractions In Vitro Lin-CB cells were sorted into CD34+CD38−/lowCD45RA− (HSC- and MPP-containing fraction) and CD34+CD38+ (Progenitors). (A) DSB rejoining measured after 15 Gy IR via the neutral comet assay in HSC/MPP (blue bars) and Progenitor (red bars) fractions. Percent of initial olive tail moment (OTM) was calculated by dividing OTM at each time point by OTM immediately after IR. 150–350 nuclei were scored for each time point (bars represent means ± SE, ∗p < 0.005). (B) Number of γH2AX foci per cell in HSC/MPP and Progenitor subpopulations 1 and 12 hr after damage. 80–120 nuclei were scored for each time point (bars represent means ± SE, ∗p < 0.001). (C) Representative immunofluorescence staining for γH2AX (red) and DNA (blue) in HSC/MPP- and Progenitor-enriched fractions 1 and 3 hr after 3 Gy IR. (D) Assessment of cell death in sorted primitive HSC, MPP, and Progenitor fractions 18 hr post IR by double staining with Annexin and 7-AAD (n = 3). (E) Survival of clonogenic progenitors from HSC, MPP, and progenitor fractions calculated by dividing number of colonies scored in the irradiated plate by the number of colonies from the same fraction counted in the nonirradiated plate (n = 3, bars represent means ± standard deviation, ∗p < 0.05 between progenitors and other fractions). See also Figure S1. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 2 Inactivation of p53 and Overexpression of Bcl-2 in Lin-CB (A) Diagrams of the lentiviral vectors used for inactivation of p53 (H1-shp53-GIP and MA-GSE56) and overexpression of Bcl-2. Control vectors are: H1-shRFP for shRNA interference, MA for GSE56 and Bcl-2 overexpression. (B) Left: western blot analysis of p53 protein levels in TEX cell line after infection with shp53 and IR with 3 Gy. Right: western blot analysis of p53 and Bcl-2 protein levels in CB cells infected with either control (MA), GSE56-, or Bcl-2-expressing lentiviruses. Accumulation of inactive p53 protein is visible as a result of GSE56 overexpression. (C) Analysis of p53 mRNA and p53 target genes 4 days after shp53 lentiviral transduction of Lin-CB cells. Relative expression levels of the indicated genes were determined by Q-PCR. Profiling of p21, PUMA, and Killer/DR5 by Q-PCR in Lin-CB-expressing shRFP, shp53, MA, GSE56, and Bcl-2 (nonirradiated [NT], white bars; 3 hr post IR [IR], black bars). Representative experiments are separated by vertical lines. Gene-specific expression levels were normalized to the levels of the GAPDH housekeeping control for the same cDNA sample. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 3 p53, Bcl-2, and ASPP1 Regulates Apoptosis and Survival of Lin-CB Cells after IR (A) Apoptosis of EGFP+ population was analyzed by annexin staining and flow cytometry 18–24 hr after 3 Gy IR. Results obtained separately for shRFP and MA (designated Ctrl thereafter), as well as for shp53 and GSE56 (designated p53KD [knockdown]) showed similar trend and therefore were combined for mean calculations (n = 2–8). (B) Clonogenic potential (CFC) of sorted Lin-CB Ctrl, p53KD-, or Bcl-2-overexpressing cells (n = 5–11). (C) Relative expression of ASPP1 in CD34+CD90+ and CD34+CD90− cells isolated after 4 days of ex vivo culture. (D and E) Lin− CB cells were transduced with the indicated shRNAs, sorted 4 days later into CD34+CD90+ and CD34+CD90− fractions followed by 3 Gy IR. Apoptosis was analyzed by annexin staining and flow cytometry 18–24 hr post-IR. Bars represent means ± standard deviation, ∗p < 0.05 versus Ctrl. See also Figure S2. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 4 Effect of p53 Inactivation or Bcl-2 Overexpression on Long-Term Myelopoiesis In Vitro Four days after lentiviral transduction, EGFP+ cells were sorted from control (MA), GSE56-, or Bcl-2-overexpressing groups, divided into two groups (NT and IR with 3 Gy), and placed into long-term cultures (100,000 cells per culture). (A) Cell expansion. (B) CD34+ cell number per culture as analyzed by flow cytometry. (C) CFC dynamics in cultures (n = 3). See also Figure S3. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 5 Repopulating Potential of Genetically Modified HSCs after IR (A) Study design. Lin-CB cells were transduced with Ctrl (shRFP or MA), p53KD (shp53 or GSE56), or Bcl-2 lentiviruses, cultured for 4 days, sorted for EGFP+ cells, divided into two groups (NT and IR with 3 Gy), and injected intrafemorally into preconditioned immunodeficient mice. Seven to ten weeks later, the secondary transplants were performed and mice were analyzed again 7–10 weeks later. (B and C) Human engraftment of the nonirradiated (B) and irradiated (C) Lin-CB cells in the injected femurs (RF) and in the noninjected bones (BM) of primary recipients. Each symbol stands for engraftment level in one recipient. Horizontal lines represent median for each group, ∗p < 0.05 in comparison with relevant Ctrl group (n = 6). See also Figure S4 and Tables S1 and S2. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 6 Effect of p53 Inactivation and Bcl-2 Overexpression on DNA Damage Accumulation and HSC Self-Renewal (A) γH2AX foci distribution in Lin− human hematopoietic cells isolated from primary and secondary recipients of cells transduced with MA, GSE56, and Bcl-2 lentiviruses. Percent of cells with <1, 1–5, and >5 foci per nucleus is depicted. (B and C) Comparison of human engraftment in the injected femurs between primary and secondary recipients. Nonirradiated (B) and irradiated (C) cells were retransplanted to assay HSC self-renewal ability. Horizontal lines represent median for each group, ∗p < 0.05 in comparison with relevant experimental group. Cell Stem Cell 2010 7, 186-197DOI: (10.1016/j.stem.2010.05.016) Copyright © 2010 Elsevier Inc. Terms and Conditions